The main objective of this trial is to investigate the effect of bosentan, a moderate Cytochrome P450 (CYP) 3A inducer on the single dose pharmacokinetics of nerandomilast.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
16
Nerandomilast
Bosentan
Humanpharmakologisches Zentrum Biberach
Biberach, Germany
Area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the last quantifiable data point (AUC0-tz)
Time frame: Up to 4 days
Maximum measured concentration of the analyte in plasma (Cmax)
Time frame: Up to 4 days
Area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity (AUC0-∞)
Time frame: Up to 4 days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.